NCT06233981 2026-04-17
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
Clinical Trials
27 trialsNCT07518706 2026-04-09
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07413354 2026-02-17
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
Tongji Hospital
Phase 2 Recruiting
NCT07363512 2026-01-23
Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT05366829 2026-01-20
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT05532319 2025-12-30
FRONT-1
Guangxi Medical University
Phase 2 Completed
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT05622071 2025-11-17
HESTIA
UNICANCER
Phase 2 Completed
NCT07078305 2025-07-22
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07047586 2025-07-03
LEAF-01
Fudan University
Phase 2 Recruiting
NCT06420440 2025-05-01
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Tongji Hospital
Phase 2 Recruiting
NCT04802876 2025-03-21
ACROPOLI
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT04401800 2025-03-10
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
BeiGene
Phase 2 Completed
NCT05920863 2025-02-11
Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT04615143 2025-01-09
TALENT
Sun Yat-sen University
Phase 2 Recruiting
NCT03419897 2024-10-26
Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
BeiGene
Phase 2 Completed
NCT06232759 2024-06-10
TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma
Guangxi Medical University
Phase 2 Completed
NCT06253598 2024-03-07
Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma
The First Affiliated Hospital of Bengbu Medical University
Phase 2 Not yet recruiting
NCT06210334 2024-02-20
HAI-TL
Eastern Hepatobiliary Surgery Hospital
Phase 2 Unknown
NCT05897268 2023-06-27
CASTLE-10
Fudan University
Phase 2 Unknown
NCT05897138 2023-06-13
A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT04663035 2023-03-22
Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC
Sun Yat-sen University
Phase 2 Unknown
NCT05407519 2023-03-22
A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
Anhui Provincial Hospital
Phase 2 Recruiting
NCT05545124 2022-09-19
Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence
Henan Cancer Hospital
Phase 2 Unknown
NCT04981665 2022-01-05
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
Zhejiang University
Phase 2 Unknown
NCT04996446 2021-08-09
ALPPS Combined With Tislelizumab in Liver Malignancy
Fudan University
Phase 2 Unknown
NCT04652492 2020-12-03
Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma
Zhongda Hospital
Phase 2 Unknown